Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Avadel Pharmaceuticals.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Avadel Pharmaceuticals
Ireland Flag
Country
Country
Ireland
Address
Address
Block 10-1, Blanchardstown, Corporate Park, Ballycoolin Dublin 15
Telephone
Telephone
+353 1 485 1200
Linkedin
Linkedin

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The offering will be used for obtaining FDA approval of company's lead candidate, Lumryz, an investigational, extended-release formulation of sodium oxybate for the treatment of cataplexy or EDS in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Jefferies LLC

Deal Size: $125.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering March 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The financing will support the potential commercialization of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: RTW Investments

Deal Size: $75.0 million Upfront Cash: Undisclosed

Deal Type: Agreement March 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lumryz (sodium oxybate) is a sodium salt of GHB, a naturally occurring CNS depressant that increases dopamine levels and increases serotonin turnover. It is being developed for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once-at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS or cataplexy in adults with narcolepsy.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: Lumryz

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Presentation highlights results from a questionnaire assessing patient preference for once-nightly versus twice-nightly dosing regimen and another questionnaire assessing experiences with the second nightly dose in patients who switched from twice-nightly oxybates to FT218.


Lead Product(s): Sodium Oxybate

Therapeutic Area: Sleep Product Name: FT218

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY